Numerous evidence showed that circulatory FGF21 rise in NAFLD patients and discussed its role as a protective factor (Tucker et al., 2019; Tillman and Rolph, 2020). Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.